GRANISETRON HYDROCHLORIDE
Clinical safety rating: safe
Animal studies have demonstrated safety
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, inhibiting emetic reflex.
| Metabolism | Hepatic metabolism via CYP3A4 (major) and CYP1A2 (minor); N-demethylation and oxidation to metabolites; elimination half-life ~9-10 hours. |
| Excretion | Renal: ~12% unchanged; fecal: ~34% (as metabolites); biliary: significant contribution; total clearance is 0.38–0.51 L/h/kg. |
| Half-life | Terminal elimination half-life: 7–9 hours (range 4–14 h) in most patients; prolonged in severe hepatic impairment (up to 12–15 h). Half-life is dose-independent. |
| Protein binding | ~65% (primarily to albumin; also α1-acid glycoprotein). |
| Volume of Distribution | Approximately 2.2–3.0 L/kg (mean 2.6 L/kg), indicating extensive extravascular distribution. |
| Bioavailability | Oral: ~60% (slight variability due to first-pass metabolism; food does not affect AUC); transdermal: ~60–70% relative to IV (steady-state delivery). |
| Onset of Action | IV: Rapid (minutes); oral: ~1–2 hours (time to peak effect for prophylaxis); transdermal: steady state reached ~24–48 h, clinical effect begins within 2–4 h. |
| Duration of Action | IV: ~24 hours (supports single-dose prophylaxis); oral: ~24 hours; transdermal: up to 7 days (patch applied 24–48 h before chemotherapy). Clinical effect correlates with receptor occupancy. |
2 mg orally once daily or 1 mg intravenously twice daily; alternatively 10 mcg/kg intravenously 30 minutes before chemotherapy for prevention of nausea and vomiting.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment is recommended for patients with renal impairment, including those on dialysis. |
| Liver impairment | For Child-Pugh Class A or B: no adjustment necessary. For Child-Pugh Class C: maximum total daily dose should not exceed 2 mg per day (either oral or intravenous) due to reduced clearance. |
| Pediatric use | For prevention of chemotherapy-induced nausea and vomiting: 10 mcg/kg intravenously (max 1 mg) 30 minutes before chemotherapy, or 40 mcg/kg orally once daily (max 2 mg). Safety and efficacy in children less than 2 years have not been established. |
| Geriatric use | No specific dose adjustment is required; however, elderly patients may have reduced renal function, but no dosage modification is recommended based on age alone. Monitor for adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Generally well-tolerated with headache being the most common side effect.
| Breastfeeding | Unknown if excreted in human milk. M/P ratio not established. Caution advised; weigh benefit vs risk. |
| Teratogenic Risk | FDA Pregnancy Category B. Animal studies show no evidence of fetal harm; no adequate human studies in first trimester. Risk cannot be ruled out; use only if clearly needed. |
| Fetal Monitoring | No specific monitoring required beyond standard prenatal care. Monitor for maternal adverse effects (headache, constipation, QT prolongation with risk factors). |
■ FDA Black Box Warning
None.
| Common Effects | Weakness Headache Constipation Diarrhea Insomnia difficulty in sleeping |
| Serious Effects |
["Hypersensitivity to granisetron or any component","Concurrent use with apomorphine (may cause profound hypotension and loss of consciousness)"]
| Precautions | ["Serotonin syndrome risk when used with other serotonergic drugs","QT interval prolongation; avoid in patients with pre-existing QT prolongation, electrolyte abnormalities, or concomitant QT-prolonging drugs","Hypersensitivity reactions including anaphylaxis","Masking of progressive ileus and/or gastric distension after abdominal surgery"] |
| Food/Dietary | No significant food interactions. Grapefruit juice does not affect granisetron metabolism. Avoid alcohol as it may worsen nausea and dizziness. |
Loading safety data…
| Fertility Effects | No known effect on fertility in animal studies. Human data lacking. |
| Clinical Pearls | Granisetron hydrochloride is a 5-HT3 receptor antagonist used for prevention of chemotherapy-induced nausea and vomiting (CINV) and radiation-induced nausea and vomiting (RINV). It is more potent than ondansetron but may cause QT prolongation; monitor ECG in patients with electrolyte abnormalities, congestive heart failure, or on other QT-prolonging drugs. Less effective for delayed CINV than aprepitant. Administer intravenously over 30 seconds or as a 1 mg oral tablet twice daily. Headache and constipation are common adverse effects. |
| Patient Advice | Take granisetron exactly as prescribed; do not exceed recommended dose. · For oral tablets, take with or without food; if vomiting occurs within 30 minutes of a dose, take another tablet. · Inform your doctor if you have a history of heart rhythm problems, electrolyte imbalances, or if you are taking other medications that affect heart rhythm. · Granisetron may cause headache, constipation, or dizziness; if severe, notify your healthcare provider. · Avoid driving or operating heavy machinery if you experience dizziness or drowsiness. · Do not use granisetron for nausea that is not related to chemotherapy or radiation without consulting a doctor. |